logo

ELUT

Elutia·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ELUT fundamentals

Elutia (ELUT) released its earnings on Nov 6, 2025: revenue was 3.30M (YoY -44.26%), missed estimates; EPS was -0.19 (YoY +42.42%), missed estimates.
Revenue / YoY
3.30M
-44.26%
EPS / YoY
-0.19
+42.42%
Report date
Nov 6, 2025
ELUT Earnings Call Summary for Q3,2025
  • $88M Bio-Envelope Sale: Transformed balance sheet, providing $49M cash runway for NXT 41X development.
  • NXT 41X Innovation: Local antibiotic delivery addresses 15%-20% post-reconstruction infection rates, targeting Q1 2027 FDA approval.
  • Revenue Recovery: SimpliDerm (+18% QoQ) and cardiovascular (+28% QoQ) drive $3.3M Q3 revenue, with >80% gross margins.
  • Litigation Resolution: 94% of legacy lawsuits closed, final $0.7M liability resolved.
EPS
Revenue

Revenue & Expenses

ELUT has released its 2025 Q3 earnings report, with revenue of 3.32M, reflecting a YoY change of -9.26%, and net profit of -3.87M, showing a YoY change of -400.78%. The Sankey diagram below clearly presents ELUT's revenue sources and cost distribution.

Key Indicators

Elutia (ELUT) key financial stats and ratios, covering profitability, financial health, and leverage.
Elutia (ELUT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Elutia (ELUT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Elutia (ELUT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Elutia (ELUT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Elutia (ELUT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield